GE Healthcare, Novo Nordisk Partner to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity

Published on: 

Joint venture combines GE’s background in ultrasound technology with Novo Nordisk’s experience with metabolic diseases.

GE Healthcare and Novo Nordisk revealed plans collaborate on advancing the clinical and product development of peripheral focused ultrasound (PFUS). According to a GE press release, the technology has the potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity.


“In an era where diabetes is increasing around the globe, we are enthusiastic about the potential for ultrasound to help people live healthier lives,” said Roland Rott, President, CEO, ultrasound, GE HealthCare. “This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well. We are eager to validate and further develop this potentially groundbreaking science, as we strive to offer patients alternative treatment options for chronic diseases.”

Reference: GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound. GE Healthcare. October 19, 2023. Accessed October 20, 2023.